|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2002-5-13
|
|
pubmed:abstractText |
Bexarotene is the first synthetic rexinoid approved for the treatment of all stages of cutaneous T-cell lymphoma (CTCL) however the mechanism of bexarotene action is unknown. We examined the effects of bexarotene on induction of apoptosis and expression of its cognate receptors in well-established CTCL cell lines (MJ, Hut78, and HH).
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Annexin A5,
http://linkedlifedata.com/resource/pubmed/chemical/BIRC5 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Chromosomal Proteins, Non-Histone,
http://linkedlifedata.com/resource/pubmed/chemical/Inhibitor of Apoptosis Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Microtubule-Associated Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Retinoic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Retinoid X Receptors,
http://linkedlifedata.com/resource/pubmed/chemical/Tetrahydronaphthalenes,
http://linkedlifedata.com/resource/pubmed/chemical/Transcription Factors,
http://linkedlifedata.com/resource/pubmed/chemical/bexarotene,
http://linkedlifedata.com/resource/pubmed/chemical/retinoic acid receptor alpha
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1234-40
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12006543-Annexin A5,
pubmed-meshheading:12006543-Apoptosis,
pubmed-meshheading:12006543-Blotting, Western,
pubmed-meshheading:12006543-Cell Cycle,
pubmed-meshheading:12006543-Cell Survival,
pubmed-meshheading:12006543-Chromosomal Proteins, Non-Histone,
pubmed-meshheading:12006543-Dose-Response Relationship, Drug,
pubmed-meshheading:12006543-Flow Cytometry,
pubmed-meshheading:12006543-Humans,
pubmed-meshheading:12006543-Inhibitor of Apoptosis Proteins,
pubmed-meshheading:12006543-Lymphoma, T-Cell, Cutaneous,
pubmed-meshheading:12006543-Microtubule-Associated Proteins,
pubmed-meshheading:12006543-Neoplasm Proteins,
pubmed-meshheading:12006543-Protein Binding,
pubmed-meshheading:12006543-Receptors, Retinoic Acid,
pubmed-meshheading:12006543-Retinoid X Receptors,
pubmed-meshheading:12006543-Skin Neoplasms,
pubmed-meshheading:12006543-Tetrahydronaphthalenes,
pubmed-meshheading:12006543-Time Factors,
pubmed-meshheading:12006543-Transcription Factors,
pubmed-meshheading:12006543-Tumor Cells, Cultured
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
|
|
pubmed:affiliation |
Department of Dermatology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
